

March 12, 2021



IPO NOTE

ISSUE DETAILS

Price Band: ₹ 129 to ₹ 130

Issue Opens on: March 15, 2021

Issue Closes on: March 17, 2021

Lot Size: 115 Shares & in Multiples

thereafter

ISSUE HIGHLIGHTS

 Issue Size :
 ₹ 600 Cr.

 No of Shares :
 46,153,846

 Face Value :
 ₹ 2

Offer Structure			
Issuance	₹ in Cr.		
Fresh Issue	300		
Offer for Sale	300		
Total	600		

Issue Breakup				
Reservation for	% of Issue	₹ in Cr. (at upper band)		
QIB	50	300		
HNI	15	90		
Retail	35	210		
Total	100	600		

^{* 60%} Shares of the QIB Portion to Anchor Investors

Listing

BSE & NSE

Lead Managers

- Axis Capital Limited
- DAM Capital Advisors Limited

Registrar

Link Intime India Private Limited

ANALYST

Krishna Rana

krishna.rana@sushilfinance.com +91 22 4093 6081

SALES

Manan Divan

manan.divan@sushilfinance.com +91 22 4093 6091 / +919819819979

COMPANY OVERVIEW

Laxmi Organic Industries is a leading manufacturer of Acetyl Intermediates and Specialty Intermediates with almost three decades of experience in large scale manufacturing of chemicals. Since their inception in 1989, they have been on a journey of transformation. They initially started manufacturing acetaldehyde and acetic acid in 1992, and soon thereafter moved on to manufacturing of ethyl acetate in 1996. It is among the largest manufacturers of ethyl acetate in India with a market share of approximately 30% of the Indian ethyl acetate market. It is the only manufacturer of diketene derivatives in India with a market share of approximately 55 % of the Indian diketene derivatives market in terms of revenue in Fiscal 2020 and one of the largest portfolios of diketene products.

Their products are currently divided into two broad categories, namely the Acetyl Intermediates and the Specialty Intermediates. They have two manufacturing facilities in Mahad, Maharashtra (the "Manufacturing Facilities"), with one facility dedicated to Acetyl Intermediates and another dedicated to Specialty Intermediates, which are strategically located in proximity to several ports and each other. The company has Diversified product portfolio in various high growth industries, including pharma, agrochem, paints & coatings, printing, packaging, dyes & pigments. It has global footprint with customers in over 30 countries.

HIGHLIGHTS

- 1. Leading manufacturer of ethyl acetate with significant market share
- 2. Only Indian manufacturer of diketene derivatives.
- 3. Diversified customer base.
- 4. Strategically located manufacturing facilities, vertical integration and supply chain efficiencies
- 5. In-house research and development capabilities

Objects of the issue

- 1. Investment in subsidiary firm, Yellowstone Fine Chemicals Private Limited (YFCPL) to partly finance the capex to establish a new manufacturing facility. (₹ 60.4 Cr.)
- 2. To invest in YFCPL for financing working capital requirements. (₹ 37.74 Cr.)
- 3. To finance the capex for expansion of SI manufacturing facility. (₹ 91. 06 Cr.)
- 4. To finance business working capital requirements. (₹ 35.18)
- 5. To purchase plant and machinery for infrastructure development at SI facility. (₹ 12.57)
- 6. To make prepayment or repayment of borrowings availed by the company and subsidiary, Viva Lifesciences Pvt Ltd (VLPL). (₹ 179.31)
- 7. To meet general corporate purposes.

Company shall not receive any proceeds from the offer for sale.

OUR VIEW

Laxmi Organics was originally incorporated in the year 1989. Over the course of the past few decades, the company has grown in leaps and bounds. Over the years, the company has significantly expanded their scale of operations and global footprint with customers in over 30 countries. The company has long term relations with marquee global clients.

The company has shown Stable revenue and margin growth in the last 3 year and 6 months. However, its FY20 revenues and margins have declined marginally compared to FY19. Higher provisioning for depreciation and amortization impacted its bottom lines for FY19 and FY20, clarified management.

Financially the company earned net profit of Rs.70 Cr. on a turnover of Rs. 1,534 Cr. in FY20 & in H1FY21 it earned profit of Rs. 45 Cr. on turnover of Rs. 813 Cr. company's ROE & ROCE stands at 10.12% & 10.87% respectively on H1FY21.

The issue is priced at a P/BV of 6.19 based on its NAV of Rs. 20.99 per share as of September 31, 2020. At upper price band of $\stackrel{?}{=}$ 130, the issue is fully priced based on its P/E of around 45x at FY20 while on the basis of 6 months ended September, 2020 P/E comes around 35x.

Laxmi Organics has considerable long-term debt. In comparison to its peers, Laxmi Organics' financials are lagging behind in some parameters. If the company is able to utilise their position as a market leader in the ethyl acetate segment and maintain efficiency in the growth and expansion plans, then we might see an improvement in the company's financial parameters. Hence, considering all the above factors, we believe the issue is fully priced and has limited upside.





Brief Financials

PARTICULARS				₹ in Million
	As at Dec. 31, 2020	FY '20	FY '19	FY'18
Total Income	8,143.55	15,386.21	15,743.23	13,960.75
Total Expenditure	7,581.56	14,834.82	14,762.64	12,827.77
Profit before Tax	561.99	808.02	975.89	1,133.14
Profit after Tax	454.84	702.12	723.91	756.95
E.P.S. [diluted (Rs.)]	2.02	2.86	2.89	3.03
P/E (x)	42	45		
RONW (%)	9.65	16.45	16.13	20.01

^{*}Not Annualised

PRICE CHART (@ ₹ 130)

LOT SIZE	Amount
115	14,950
230	29,900
345	44,850
460	59,800
575	74,750
690	89,700
805	104,650
920	119,600
1,035	134,550
1,150	149,500
1,265	164,450
1,380	179,400
1,495	194,350

Please go through the RHP for salient features.

 $(https://www.sebi.gov.in/filings/public-issues/mar-2021/laxmi-organic-industries-limited-rhp_49422.html)$

Indicative Time Table

Tentative Events	Indicative Dates
Finalisation of Basis of Allotment with the Designated Stock Exchange	22/03/2021
Initiation of refunds/unblocking ASBA Fund	23/03/2021
Credit of Equity Shares to demat accounts of Allottees	24/03/2021
Commencement of trading of the Equity Shares on the Stock Exchanges	25/03/2021

March 12, 2021





Disclaimer

This report has been furnished to you for your general information only & should not be reproduced, re-circulated, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of Sushil Financial Services Private Limited. This Research Report is meant solely for use by the original recipient to whom it is sent & is not for circulation. Any unauthorized use, disclosure or public dissemination or copying of information (either whole or partial) contained herein is prohibited.

This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views &/or opinions & should not be deemed or construed to be neither advice/offer for the purpose of purchase or sale of any securities mentioned herein. Past performance is not a guide for future performance, future returns are not guaranteed. Opinions expressed herein are subject to change without notice. Investor should rely on information/data arising out of their own investigations. Investors are advised to seek independent professional advice & arrive at an informed trading/investment decision before executing any trades or making any investments.

The price & value of the investments referred to in this material & the income from them may go down as well as up, & investor may realize losses on any investments. This Report has been prepared on the basis of publicly available information, internally developed data & other sources believed by us to be reliable. Sushil Financial Services Private Limited or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy & reliability of such information / opinions / views. None of the directors, employees, affiliates or representatives of company shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages/loss etc. whatsoever from the information/opinions/views contained in this Report & investors are requested to use the information contained at their risk. We do not undertake to advise you as to any change of our views expressed in this Report.

Sushil Financial Services Private Limited (SFSPL) & its connected companies, & their respective Directors, Officers & employees or their relative, may have a long or short position in the subject companies mentioned in the report & it may not be construed as potential conflict of interest with respect to any recommendation & related information & opinions. Reports based on technical & derivative analysis center on studying charts company's price movement, outstanding positions & trading volume, as opposed to focusing on a company's fundamentals &, as such, may not match with a report on a company's fundamental analysis.

SFPSL has different business segments/Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc. & therefore may at times have different contrary views on stocks sector & markets. Research Report may differ between SFSPL's RAs on account of differences in research methodology, personal judgment & difference in time horizons for which recommendations are made. User should keep this risk in mind & not hold - SFSPL, its employees & associates responsible for any losses, damages of any type whatsoever.

This Report is not intended to be a complete statement or summary of the securities, market or developments referred to in this document. SFSPL or its affiliates or employees are under no obligation to update the information. SFSPL or its affiliates or employees shall not be in any way responsible & liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. SFSPL or its affiliates &/or its employees may have financial interest in the subject companies. SFSPL or its affiliates &/or employees may have beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report.

SFSPL or its associates or its Research Analyst have not received any compensation or other benefits from the subject companies or third party in connection with the research report. SFSPL/its Associates/ Research Analyst/ his Relatives may have any other material conflict of interest at the time of publication of the research report.

SFSPL/its Associates/ Research Analyst/ his Relatives have not managed or co-managed public offering of securities, have not received compensation for investment banking or merchant banking or brokerage services, have not received any compensation for product or services other than investment banking or merchant banking or brokerage services from the subject companies in the last twelve months.

There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

SFSPL SEBI Research Analyst (RA) No: INH000000867

March 12, 2021